Previous 10 | Next 10 |
home / stock / aavxf / aavxf news
PARIS, FRANCE / ACCESSWIRE / March 16, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces an update of its 2...
PARIS, FRANCE / ACCESSWIRE / March 13, 2023 / Abivax SA (the "Company", Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, is aware that Sili...
PARIS, FRANCE / ACCESSWIRE / February 23, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX) (the "Company" ), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces...
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR TO U.S. PERSONS Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors This financing was led by TCGX, with participation f...
Sheldon Sloan, M.D., M. Bioethics, has a strong track record in product development and commercial launches in the pharmaceutical industry with a focus on Inflammatory Bowel Disease As CMO of Abivax, Dr. Sloan will play a critical role in the successful conduct and completion of the ongoing ...
Abivax will be presenting a poster on blood and rectal tissue data from ulcerative colitis (UC) patients, confirming the novel mechanism of action of obefazimod based on the upregulation of a single microRNA, miR-124 The presentation will be given at the 18 th Congress of ECCO during the po...
The scientific article in the peer-reviewed journal Clinical and Translational Gastroenterology describes obefazimod's capacity to selectively up-regulate a single microRNA, miR-124, leading to decreases in proinflammatory cytokines and thus acting as "a physiological brake" of inflammation and t...
Arena Pharmaceuticals got acquired by Pfizer for US$ 6.7 Bn (~100% valuation) on December 12th. As a result, the market for late-stage oral IBD candidates that big pharma can acquire is thinning. After the JAKi's black-box warning and a wave of biosimilar/generics soon entering, big p...
After the recent FDA black box warning of JAKi, Arena Pharmaceuticals' share price has rallied recovering some of its 2021 losses. In this article, Etrasimod's ulcerative colitis phase 2 data will be analyzed and explain what our views for the S1P-R class moving forward. Arena Pha...
Abivax (AAVXF) said that ABX464, its candidate for ulcerative colitis ("UC") with a new mechanism of action, demonstrated reductions in multiple disease activity measurements in a phase 2b study.As a result, the French biotech will move ahead with a phase 3 trial, which is expected to start b...
News, Short Squeeze, Breakout and More Instantly...
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with ...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabi...
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...